Kardium Announces 1-Year PULSAR IDE Study Results for Its PFA Device – the Globe® PF System
VANCOUVER, British Columbia — Kardium Inc., a private medical device company that's advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed field ablation (PFA) device—the Globe PF System. These pivotal findings from the PULSAR IDE study were announced at the Heart Rhythm Society (HRS) meeting in San Diego 1, highlighting the safety and efficacy data of the Globe PF System, which is currently under PMA review with the US FDA.
Article content
Article content
Key results included:
Article content
'These impressive one‑year efficacy results underscore the advanced catheter design of the Globe PF System,' said Dr. Vivek Reddy, Co-Principal Investigator from The Mount Sinai Fuster Heart Hospital, New York. 'Given the excellent durability achieved by the Globe PF System, the efficacy result is likely approaching the limit of what we can achieve with PV isolation alone.'
Article content
With just 1.2 applications per vein, the Globe PF System is the true single-shot PFA solution with integrated mapping and ablation built into a single catheter.
Article content
'We are very pleased with the study's safety results,' says Dr. Atul Verma, Co-Principal Investigator from McGill University Health Centre in Montreal. 'The Globe PF System has demonstrated an exceptional safety profile and offers many key safety differentiators. Its unique design provides single-shot energy application with precise ablation control that allows us to make individualized patient‑centered treatment decisions.'
Article content
The PULSAR IDE study is a global, prospective, multicenter, single-arm study to demonstrate the safety and long-term efficacy of the Globe PF System. The study enrolled 183 patients across 12 centers in the United States, Europe, and Canada with symptomatic paroxysmal atrial fibrillation. The data presented at HRS was preliminary and the full data will be included in a publication.
'These are truly outstanding results from the PULSAR IDE study,' said Kevin Chaplin, CEO of Kardium. 'The Globe PF System achieved incredible results for safety, efficacy, durability, PFA applications and procedure times. This study is another big step towards achieving our mission at Kardium of delivering the best treatment for atrial fibrillation.'
Article content
Atrial fibrillation is the most common type of cardiac arrhythmia and affects more than 8 million people in the United States and nearly 50 million people worldwide. 2 Unlike other catheter ablation systems, the Globe PF System is the only solution of its kind to combine single-shot PV isolation, advanced mapping and atrial ablation into a single catheter.
Article content
About Kardium
Article content
We are a rapidly growing, privately held medical solutions company made up of a team of scientists, engineers, creatives and business professionals. Our mission is to deliver the best treatment for atrial fibrillation.
Article content
Article content
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. This press release may contain forward-looking statements, which reflect current expectations regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, performance or achievements to be materially different from those expressed or implied by such statements.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
03-07-2025
- Globe and Mail
Kardium raises $340-million as B.C. heart device maker prepares for FDA approval, market entry
A Vancouver-area company that is poised to bring the most effective technology to market for treating a common heart problem has raised $340-million from investors. Kardium Inc., developer of a treatment for atrial fibrillation (AF), said the deal, announced Wednesday, was led by Janus Henderson Investors, sovereign wealth fund Qatar Investment Authority, MM Capital, Piper Heartland Healthcare Capital, Eventide Asset Management and Eckuity Capital. Existing backers including T. Rowe Price Investment Management Inc. and Durable Capital Partners also participated, plus an unidentified strategic investor. Hedge fund MM is the sole Canadian player in the deal. AF is an irregular heartbeat disorder that affects more than 59 million people worldwide, and causes strokes and failures. Kardium, which has previously raised more than US$300-million, is one of several players bringing devices to market that treats AF with a method called pulsed field ablation. Kardium could be poised for rapid commercial success after receiving Class 3 medical device approval from the U.S. Food and Drug Administration, which chief executive officer Kevin Chaplin said in an interview he expects this year. Few Canadian companies have received that stringent designation, reserved for devices posing the highest potential health risk. Boston Scientific Corp. generated US$1-billion in sales from its PFA device in 2024, after winning FDA approval that year. Medtronic plc, an American-Irish company, expects similar sales for its PFA product. 'This is a huge market, and it's one of the fastest-growing areas in medtech,' Mr. Chaplin said. Kardium has generated better clinical results than both rivals. In April, it published results from a study of 183 patients showing 77.8 per cent were free of AF 12 months after being treated with its technology, with no device-related 'primary safety events.' Other developers of PFA devices reported between 0.7 per cent and 2.2 per cent adverse safety events, while their treatments kept 66.7 per cent to 73.3 per cent of patients AF-free for a year. A procedure using Kardium's technology also takes less time than with competing devices. Kardium 'knocked it out of the park on that data,' said Janus portfolio manager Aaron Schaechterle in an interview. 'We think it has the strongest product in what in our opinion will be a close to US$10-billion market. The company should be able to generate its rightful share' of the category. He added that Kardium's success will 'come down to execution. It's a small company with a single product going up against some of the biggest companies in cardiology and medical technology. That challenge requires a scrappy and entrepreneurial management team, and we believe the Kardium is up to the challenge.' The 500-person company is expanding its manufacturing, now done at its facilities in Burnaby, B.C., and plans to hire hundreds of people to make and sell the product. Kardium expects to sell its devices for US$8,000 to US$10,000 each. Kardium's technology combines several existing approaches that treat different aspects of AF into a single device designed to save time and improve results. B.C. biotech boom: Vancouver looks to join the global big leagues of modern medicine The key is a three-centimetre-diameter disco ball-like globe with 122 golden, individually controlled electrodes. The sphere is flattened, encased in a sheath, inserted in a patient's femoral vein and threaded into the heart's left atrium. It is then expanded to sphere form and maps the inside of the heart to pinpoint where erratic electrical signals originate before destroying the problem cells. The device was originally designed to burn the cells using radio frequencies. But in 2021, Kardium shifted to the emerging PFA approach, whereby its device sends rapid, high voltage pulses to rupture targeted cells, restoring the heart's normal rhythms without damaging adjacent cells like the older approach. Kardium, established in 2008, grew out of conversations between Dr. Sam Lichtenstein, former head of the University of B.C.'s cardiac surgery division, and Daniel Gelbart, former chief technology officer of B.C. tech pioneer Creo Inc., whose name is on dozens of Kardium patents. Dr. Lichtenstein was frustrated by limitations of existing tools to improve patient outcomes for heart conditions. He and Mr. Gelbart, now company advisers, brainstormed ideas to fix the problem. Creo's former CEO, Amos Michelson, joined as chair to turn their ideas into a business. Former Creo employee Doug Goertzen became Kardium's first CEO (he's now president and chief operating officer). Nine years after its founding, Kardium began human trials, which were successful. But it had to do a new trial after switching to the PFA approach. Mr. Chaplin said that once Kardium gets FDA approval, it will seek approval from health authorities in Canada and Europe and aim to go public in 2026. After a three-year drought for life sciences initial public offerings, the market has started opening up, with three IPOs by medical device companies on U.S. exchanges (CeriBell, Inc. Beta Bionics Inc. and Kestra Medical Technologies, Ltd.) since last fall. David Martin, an analyst with Toronto life sciences investment bank Bloom Burton, said Kardium could also be an acquisition target. 'This has the potential to be best-in-class, which isn't always the case, therefore the potential here is substantial,' he said in an interview.
National Post
02-07-2025
- National Post
Kardium Announces $250M (CA$340M) Financing to Launch Innovative Atrial Fibrillation Treatment
Article content VANCOUVER, British Columbia — Kardium Inc., the developer of the Globe ® Pulsed Field System – an innovative treatment for atrial fibrillation (AF) – has raised US$250 million in a new financing round. Article content Article content The oversubscribed round was led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors also participated, including funds and accounts advised by T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Durable Capital Partners LP. The financing also includes an equity investment from a leading strategic investor. Article content 'We're thrilled to have secured this transformational financing with a world-class syndicate of investors,' said Kevin Chaplin, CEO of Kardium. 'This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.' Article content 'We are delighted to join Kardium as an investor,' said Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors. 'The Globe System is a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation. This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardium's groundbreaking technology to the market.' Article content Impressive clinical data from the pivotal PULSAR clinical study of the Globe System was recently presented at the 2025 Heart Rhythm Society annual meeting. This data demonstrated remarkable results with the Globe System, showing freedom from atrial arrhythmia at 1 year of 78% in paroxysmal AF patients, with 0% device-related primary safety events. i The new funding will enable Kardium to pursue regulatory approvals for the Globe System, further expand its manufacturing facilities and production capacity, and establish a clinical support and commercial team in preparation for the anticipated commercial launch of the Globe System later this year. It will also enable Kardium to run further clinical research for additional applications and expanded indications for the Globe System. Article content The Globe Pulsed Field System consists of a sophisticated catheter with a 122-electrode array and advanced software that enables rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium – all with a single catheter. Article content About Kardium Article content Kardium Inc. ( is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe System. Kardium has built an outstanding team, who have worked with top medical advisors to develop the Globe System. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has consistently ranked as one of the top companies to work for in British Columbia. Article content This press release may contain forward-looking statements, which reflect current expectations regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, performance or achievements to be materially different from those expressed or implied by such statements. The Globe System is restricted by federal law to investigational use only, and it has not been approved or cleared for commercial distribution in any jurisdictions. Article content Article content Article content Article content
CTV News
22-05-2025
- CTV News
Two Sudbury nurses hope to close the gap in perinatal mental health care
YMCA Canada CEO launches national tour in Sudbury, urging partnerships to tackle isolation and mental health crises amid declining community ties.
